	US 12,410,424 B2
	Diagnosis of prostate cancer
Heather R. Sanders, Winchester, CA (US)
Assigned to Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed by Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed on Jun. 5, 2023, as Appl. No. 18/205,795.
Application 18/205,795 is a continuation of application No. 16/887,079, filed on May 29, 2020, granted, now 11,667,909.
Application 16/887,079 is a continuation of application No. 15/952,452, filed on Apr. 13, 2018, granted, now 10,669,536.
Application 15/952,452 is a continuation of application No. 15/593,921, filed on May 12, 2017, granted, now 9,963,695.
Application 15/593,921 is a continuation of application No. 13/997,868, granted, now 9,663,781, previously published as PCT/US2011/067880, filed on Dec. 29, 2011.
Claims priority of provisional application 61/428,750, filed on Dec. 30, 2010.
Prior Publication US 2023/0407289 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12N 15/10 (2006.01); C12P 19/34 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6886 (2018.01)

CPC C12N 15/1017 (2013.01) [C12Q 1/6806 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/158 (2013.01)]

18 Claims

1. A detection method comprising:

(a) separating urine sediment from a whole urine sample to prepare a soluble urine fraction; and

(b) determining the amount of RNA from each of heat shock 60 kDa protein 1 (HSPD1), inosine monophosphate dehydrogenase 2 (IMPDH2), PDZ and LEVI domain 5 (PDLIM5), and UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1).